We recently recapped the law relating to when experts are allowed to opine on what was in the head of another and how a pending Supreme Court criminal case might affect things. In our area, this issue comes up most frequently in the context of plaintiff experts trying to offer their spin about how the
Questionable California Cough Medicine Consumer Class Lingers
We have seen a number of consumer fraud class action cases brought over a range of fairly ticky tacky issues about OTC drugs and consumer products. California law and courts have been fairly favorable to these cases, which follow a pattern of a test plaintiff seeking to represent some large class because (s)he claims to
The State of State of Mind Testimony by Experts
The issue of the state of mind or intent of a party can play out a number of ways based on the nature of the case. In the criminal context, proof of the mens rea of the defendant is typically an element in the statutory definition of the crime. In a civil contract case, whether
Guest Post – Another Potentially Bubbly Battle Over Hydrogen Peroxide Fizzles Out
Today’s guest post is by Amy McVeigh and Jessica Farmer, who are partners at Holland & Knight. They comment on the demise of another purported class action against a manufacturer of hydrogen peroxide, which is an FDA-regulated over-the-counter (“OTC”) drug. As always our guest posters deserve 100% of the credit (and any blame)
California Federal Court Holds Onto Purported Class To Dismiss It Under The PREP Act
Much like the placement of a comma, differences in capitalization can affect meaning quite a bit. Take PrEP and PREP. The former refers to the use of certain antiviral medications for pre-exposure prophylaxis to HIV, which has been hailed as a paradigm shift in treating HIV. We recall that FDA was so impressed with
Sell or Don’t Sell: Liability May Await Either Way
For many years, even before the Supreme Court picked up the ball, we have been arguing that “stop selling” theories of liability for alleged injuries from prescription drugs should not be viable. This is not just a preemption issue. Basic product liability principles do not square easily with liability contingent on developing one drug
Double Shot Thursday: “The More Things Change” And “Of Puppets And Standing”
As insightful and modest as the Blog can be, we are not infallible. Every once in a while, two posts get written on the same decision, sometimes because we try to make sure a new post goes up every non-holiday weekday of the year. Because of the aforementioned modesty, however, we are hesitant to deprive
Federal Officer Removal Fails In California
It is a simple fact that product liability plaintiffs almost always prefer state court and product liability defendants almost always prefer federal court. This is a major reason why removal fights, sometimes intertwined with personal jurisdiction fights, happen so often in these types of cases. Another reason is that product liability plaintiff lawyers like to
The Expanding Breadth Of Nexus
Back in 2020, we noted the possible broad implications of a Buckman preemption decision in a somewhat unusual economic loss case that turned on whether a compounded pharmaceutical needed FDA approval through an NDA. When that case, Nexus Pharms., Inc. v. Cent. Admixture Pharm. Servs., Inc., 48 F.4th 1040 (9th Cir. 2022), was affirmed
Generic Causation Experts Excluded In Sweeping Ruling From The Acetaminophen MDL
It is not uncommon that terms are used without knowledge of their origin and that the origin is instructive about the meaning or proper application of the term. We offer two examples. Many lawyers who at least dabble in product liability litigation have heard the term “Bradford Hill criteria.” Was it named after two different